Healthcare must shift from treatment to prevention, liver disease is the wake-up call

India’s health economy has been engineered around rescue. Tertiary capacity, transplant programmes, intensive care capabilities and surgical volume have all scaled at a pace few emerging economies have matched, and Indian outcomes in complex hepatobiliary work now stand comparison with those of any centre in the world. Detection has not kept up. What has emerged is a system that performs exceptionally at the most expensive point on the disease curve and thinly at the cheapest one. Liver disease is where that imbalance is most exposed.

The scale is not in question. Work published in Clinical Liver Disease (1) found that India alone accounted for 18.3 per cent of global liver disease deaths, the largest national share of a burden running into millions. Beneath that mortality figure sits a far larger reservoir of silent disease. Fatty liver, now classified as metabolic dysfunction-associated steatotic liver disease (MASLD), is present across a substantial share of urban Indian adults and in the majority of patients attending diabetes clinics. Almost all of them feel entirely well. A condition that generates no symptoms generates no revenue signal either, which is precisely why the sector keeps meeting it fifteen years too late.

The arithmetic of arriving late

Cost is where the argument becomes commercial rather than clinical. A Fibrosis-4 (FIB-4) score, the tool recommended for risk stratification, is calculated from age, platelet count, and two liver enzymes already present on any routine panel, which makes early identification close to cost-neutral. Transient elastography adds a few thousand rupees.

Set against that, a liver transplant at leading Indian centres is reported to cost between ₹15 lakh and ₹40 lakh (2), with lifelong immunosuppression and surveillance required thereafter. Few line items anywhere in Indian healthcare carry an intervention gap of that magnitude. The clinical case for early detection was settled years ago. The financial case is arguably stronger, and it remains largely unclaimed.

Who captures that saving is the question the sector has avoided answering.

Where the financing pressure is already building

Public spending is rising, though not fast enough to absorb a metabolic epidemic. National Health Accounts data cited by the Press Information Bureau (3) shows government health expenditure climbing from 1.13 per cent of GDP in 2014–15 to 1.84 per cent in 2021–22, with per capita health spending tripling from ₹1,108 to ₹3,169 over the same period. Real progress. It is also progress that a single wave of late-stage metabolic liver disease could comfortably outrun, given that assured cover under national insurance sits well below the cost of a transplant.

Private payers face the same equation without the cushion. Underwriting a fibrosis assessment for a policyholder already carrying diabetes or central obesity costs a fraction of underwriting the decompensation that follows, yet structured liver risk stratification still sits outside most wellness benefits rather than inside them. Employers absorb the residue through absence and lost mid-career leadership, since the cohort now presenting with advanced fibrosis is the cohort running businesses.

Capital has read the situation more quickly than providers have. Investment continues to flow toward diagnostics networks, metabolic clinics, and longitudinal monitoring on the reasonable thesis that Indian households will pay for information about risk before they pay for treatment of disease. Hospitals that treat screening as a loss leader misread their economics. A structured detection programme converts a one-off, high-acuity, frequently unfunded late admission into a durable clinical relationship spanning:

• Hepatology
• Endocrinology
• Nutrition & Lifestyle Medicine
• Cardiology
• Metabolic Surgery

Lifetime patient value rises. Dependence on emergency presentation falls.

Policy has travelled further than practice

Government intent is not the constraint. Announcing the integration of fatty liver disease into the national non-communicable disease programme, the Ministry of Health and Family Welfare stated (4) that India had become the first country in the world to identify the need for action on the condition, framing the wider vision as a move from diagnostic cure to preventive health. The operational guidelines now in force (5) push risk assessment down to the Ayushman Arogya Mandir level, where community health officers can flag suspects long before a specialist is involved.

Execution is the gap. An abnormal result that lands in a register without triggering a referral costs the system money and provides no benefit. Corporate health check packages that print a raised liver enzyme and move on have done the same. Closing those loops requires no new technology and very little capital, only the discipline of a structured pathway that carries a patient from evaluation to a clear explanation of options and then to follow-up.

That discipline is what separates a health system that reacts from one that anticipates. Indian healthcare has spent three decades proving what it can salvage. Its next chapter will be judged on what it prevents, because no payer, public or private, can finance a metabolic epidemic one transplant at a time. The maturity of a liver programme is not measured by the transplants it performs. It is measured by the transplants it makes unnecessary.

References: 

1. https://journals.lww.com/cld/fulltext/10.1002/cld.1177~epidemiology-of-liver-diseases-in-india 
2. https://www.apollo247.com/health-topics/liver-disease/liver-transplant-cost-in-india 
3. https://www.pib.gov.in/PressNoteDetails.aspx?ModuleId=3&NoteId=153407 
4. https://www.pib.gov.in/PressReleasePage.aspx?PRID=1699904&reg=48&lang=2 
5. https://www.mohfw-dohfw.gov.in/static/uploads/2025/11/c8005dd96fe039dc7e30e0867a50de3e.pdf